潘弘偉 博士


    分子醫學研究室 高級助理研究員 
    潘弘偉(Hung-Wei Pan)


    1. 高級助理研究員   高雄榮民總醫院 教學研究部 (2011~)
    2. 博士後研究員  臺大醫院病理部、外科部 (2007~2011)
    3. 部定助理教授 (助理教字第037572號) (2013~)

    Art editor Img


    1. 助理教授(兼任) 屏東大學應用化學系(2015~)
    2. 助理教授(兼任) 大仁科技大學 藥學系(2012~2013)
    3. 助理教授 (兼任) 國立臺灣師範大學國際與僑教學院僑先部生物學科(2010~2012)
    1. 博士 國立台灣大學 病理學學研究所 (2007)
    2. 碩士 國立陽明大學 醫學生物技術研究所 (2000)
    3. 學士 東海大學 生物系 (1994)
    1. 2007 Poster Presentation, AACR-ITO EN, Ltd. Scholar-in-Training Award for the AACR (American Association for Cancer Research) Annual Meeting 2007, Los Angeles, USA.
    2. 2007 Excellent Research Paper Award from Dr. Chien-Tien Hsu’s Foundation, The 15th Symposium on Recent Advances in Cellular and Molecular Biology, Taiwan. (第15屆細胞及分子生物新知研討會,徐千田論文口頭報告比賽佳作)
    3. 2004 Grant Award from the Liver Disease Prevention & Treatment Research Foundation, Taipei, Taiwan. (財團法人肝病防治學術基金會,研究獎助金)
    1. Liver Cancer Pathology (肝癌病理)
    2. Molecular Epidemiology (分子流行病學)
    3. Cancer biology (腫瘤生物學)
    4. Molecular and Cell Biology (分子及細胞生物學)
    1. 染色體不穩定相關基因分子病理學研究
    2. 新穎染色體分配基因的訊息傳遞
    3. 核酸藥物篩選
    1. 染色體不穩定(chromosomal instability / CIN) 是在人類癌症常見的異常。在腫瘤治療中,抗藥性和染色體不穩定性與腫瘤的不良預後有關,使腫瘤治療有相當大的挑戰。
    2. 本實驗室專注於研究染色體不穩定與癌症之間的相關性,可以作為診斷或預後標誌。經由抑制這些相關基因表達,便能夠發展新的治療策略。

    Art editor Img

    (A) Chapter of Book

    1. Leung CM, Tsai KW, Pan HW. DNA methylation in aggressive gastric carcinoma. Gastric Carcinoma- New Insights into Current Management, ISBN 978-953-51-0914-3, edited by Daniela Lazăr. Published: January 23, 2013 under CC BY 3.0 license. (corresponding author) (http://dx.doi.org/10.5772/52135)

    (B) 原始著作 Articles:
    *: corresponding author

    1. Hsu CW, Chen YC, Su HH, Huang GJ, Shu CW, Wu TT, Pan HW. Targeting TPX2 Suppresses the Tumorigenesis of Hepatocellular Carcinoma Cells Resulting in Arrested Mitotic Phase Progression and Increased Genomic Instability. Journal of Cancer. 2017 (in press)
    2. Huang WC, Ke MW, Cheng CC, Chiou SH, Wann SR, Shu CW, Chiou KR, Tseng CJ, Pan HW, Mar GY, Liu CP. Therapeutic Benefits of Induced Pluripotent Stem Cells in Monocrotaline-Induced Pulmonary Arterial Hypertension. PLoS One. 2016 Feb 3;11(2):e0142476.
    3. Hou YY, You JJ, Yang CM, Pan HW, Chen HC, Lee JH, Lin YS, Liou HH, Liu PF, Chi CC, Ger LP, Tsai KW. Aberrant DNA hypomethylation of miR-196b contributes to migration and invasion of oral cancer. Oncol Lett. 2016 Jun;11(6):4013-4021
    4. Tsai KW, Li GC, Chen CH, Yeh MH, Huang JS, Tseng HH, Fu TY, Liou HH, Pan HW, Huang SF, Chen CC, Chang HY, Ger LP, Chang HT. (2015, Aug). Reduction of global 5-hydroxymethylcytosine is a poor prognostic factor in breast cancer patients, especially for an ER/PR-negative subtype.. Breast Cancer Res Treat. , 153(1):219-34.
    5. Liu PF, Leung CM, Chang YH, Cheng JS, Chen JJ, Weng CJ, Tsai KW, Hsu CJ, Liu YC, Hsu PC, Pan HW*, Shu CW*. ATG4B promotes colorectal cancer growth independent of autophagic flux. Autophagy. 2014 Aug;10(8):1454-65. (*co- corresponding author)
    6. Chen WS, Chen TW, Yang TH, Hu LY, Pan HW, Leung CM, Li SC, Ho MR, Shu CW, Liu PF, Yu SY, Tu YT, Lin WC, Wu TT, Tsai KW. Co-modulated behavior and effects of differentially expressed miRNA in colorectal cancer. BMC Genomics. 2013;14 Suppl 5:S12. doi: 10.1186/1471-2164-14-S5-S12. Epub 2013 Oct 16.
    7. Pan HW, Li SC, Tsai KW. MicroRNA dysregulation in gastric cancer. Curr. Pharm. Design. Curr Pharm Des. 2012 Sep 25. [Epub ahead of print]
    8. Chen WS, Leung CM, H. W. Pan HW, Hu LY, Li SC, Ho MR, Tsai KW. Silencing of miR-1-1 and miR-133a-2 cluster expression by DNA hypermethylation in colorectal cancer. Oncol. Rep. 2012; 28(3):1069-76.
    9. Chang HT, Li SC, Ho MR, Pan HW, L. Y. Hu LY, Yu SY, Ger LP, Tsai KW. Comprehensive analyses of microRNAs in breast cancer, BMC Genomic 2012;13 Suppl 7:S18. (doi: 10.1186/1471-2164-13-S7-S18. Epub 2012 Dec 13).
    10. Li SC, Tsai KW, Pan HW, Jeng YM, Ho MR, Li WH. MicroRNA 3' end nucleotide modification patterns and arm selection preference in liver tissues, BMC Systems Biology 2012;6 Suppl 2:S14. (doi: 10.1186/1752-0509-6-S2-S14. Epub 2012 Dec 12).
    11. Lin ZZ, Jeng YM, Hu FC, Pan HW, Tsao HW, Lai PL, Lee PH, Cheng AL, Hsu HC. Significance of Aurora B overexpression in hepatocellular carcinoma. BMC Cancer. 2010 Aug 28;10(1):461.
    12. Wang YC, Chen YL, Yuan RH, Pan HW, Yang WC, Hsu HC, Jeng YM. Lin-28B expression promotes transformation and invasion in human hepatocellular carcinoma. Carcinogenesis. 2010 Sep;31(9):1516-22.
    13. Lin SY*, Pan HW*, Liu SH, Jeng YM, Hu FC, Peng SY, Lai PL, Hsu HC. ASPM is a novel marker for vascular invasion, early recurrence and poor prognosis of hepatocellular carcinoma. Clin Cancer Res. 2008 ; 14(15):4814-20. (*: equal contribution) 
    14. Cheng W, Tseng CJ, Lin Tom-TC, Cheng I, Pan HW, Hsu HC, Lee YM. Glypican-3-mediated oncogenesis involves the IGF signaling pathway. Carcinogenesis. 2008; 29(7):1319-26.
    15. Peng SY, Lai PL, Pan HW, Hsiao LP, Hsu HC. Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncology Reports. 2008;19: 1045-1053. 
    16. Yuan RH, Jeng YM, Pan HW, Hu FC, Lai PL, Lee PH, Hsu HC. Overexpression of KIAA0101 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma. Clin Cancer Res. 2007; 13(18):5368-76.
    17. Liu CL, Yu IS, Pan HW, Lin SW, Hsu HC. L2dtl is essential for cell survival and nuclear division in early mouse embryonic development. J Biol Chem. 2007; 282(2):1109-18.
    18. Lee YC*, Pan HW*, Peng SY, Lai PL, Kuo WS, Ou YH, Hsu HC. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur J Cancer. 2007; 4:736-44. (*: equal contribution) 
    19. Pan HW, Chou H-Y E, Liu SH, Peng SY, Liu CL, Hsu HC. Role of L2DTL, Cell cycle-regulated nuclear and centrosome protein, in aggressive hepatocellular carcinoma. Cell Cycle. 2006; 5(22):2676-87.
    20. Yuan RH, Jeng YM, Chen HL, Lai PL, Pan HW, Hsieh FJ, Lin CY, Lee PH, Hsu HC. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol. 2006; 209(4):549-58.
    21. Peng SY, Ou YH, Chen WJ, Li HY, Liu SH, Pan HW, Lai PL, Jeng YM, Chen DC, Hsu HC. Aberrant expressions of annexin A10 short isoform, osteopontin and alpha-fetoprotein at chromosome 4q cooperatively contribute to progression and poor prognosis of hepatocellular carcinoma. Int J Oncol. 2005; 26(4):1053-61. 
    22. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, and Hsu HC. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 2003; 98(1):119-127.
    23. Liu SH, Lin CY, Peng SY, Jeng YM, Pan HW, Lai PL, Liu CL, Hsu HC. Down-regulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation. Am J Pathol 2002; 160(5):1831-7

    (C)Thesis (論文)

    1. Master Thesis (August, 2000):Cloning, Expression and Hypomethylation of Osteopontin in Hepatocellular Carcinoma: potential association with tumor progression. Institute of Biotechnology in Medicine, National Yang-Ming University, Taipei, Taiwan.
    2. Ph. D. Dissertation (January, 2007): Role of L2DTL in Hepatocellular Carcinoma. Graduate Institute of Pathology, National Taiwan University, Taipei, Taiwan.

    (D)Poster Presentation (壁報發表)

    1. 2016/04  Shiou-Rong Wu, Chung-Man Leung, Chao-Wen Hsu , Huai-Hsing Chen , Jin-Lian Wu, Ju-I Tsai, Hung-Wei Pan. The Role of NDC80 in Colon Cancer Progression, Altered Genomic Instability and Its Therapeutic Potential. (April 16-17, 2016, 中國醫藥大學立夫教學大樓, Taichung, Taiwan). (2016年第八屆亞太醫學檢驗科學國際研討會)
    2. 2016/04  Hung-Wei Pan, Chao-Wen Hsu, Yu-Chia Chen, Tony Wu.Targeting TPX2 arrested cell cycle progression, raised multinuclearity, ploidy, and suppresses tumorigensis in hepatocellular carcinoma cells. AACR (American Association for Cancer Research) Annual Meeting 2015, Philadelphia, Pennsylvania, USA.
    3. 2015/04  A short ASPM splicing variant but not the full length variant as a molecular target in hepatocellular carcinoma. AACR (American Association for Cancer Research) Annual Meeting 2015, Philadelphia, Pennsylvania, USA.
    4. 2014/04  ASPM, a cell cycle regulated gene and silencing its splicing variant as a molecular target in hepatocellular carcinoma. AACR (American Association for Cancer Research) Annual Meeting 2014, San Diego, USA.
    5. 2010/12 Stathmin contribute to the liver cancer cell migration and invasion. The 50th Annual Meeting of the American Society for Cell Biology (ASCB) in Philadelphia, USA
    6. 2007/04  L2DTL encodes a nuclear and centrosome protein and its overxpression correlates with aggressive hepatocellular carcinoma. AACR (American Association for Cancer Research) Annual Meeting 2007, Los Angeles, USA 
    7. 2004/03  L2DTL (ramp) overexpression in hepatocellular carcinoma is associated with high-grade tumor, vascular invasion and poorer prognosis. AACR (American Association for Cancer Research) Annual Meeting 2004, Orlando, USA


         陳懷星, 蔡薷毅, 吳京璉, 張庭溪, 王建升, 洪筱清